There has been no even-keel or status quo in 2020; companies have either been in trouble or growth mode. Through its journey to complete its first commercial deployment and registered with the FDA, Curiato has been in the latter, all the while advancing its capabilities for smart patient monitoring of pressure injuries.Clinical validation study results were presented as clinical posters at both the Society of Advanced Wound Care (SAWC) and Wounds Canada conferences. Excitingly this research yielded patient insights for mobility, moisture, temperature, and posture. Research continued with a second study at Toronto Grace Health Centre (TGHC) exploring how real-time detection and notification of interface pressure and microclimate might prioritize care and impact staff workflow efficiency when used in conjunction with existing pressure injury prevention standard of care practices.
The most recent study collected data for 96 hours. During the first 48 hours, the system recorded in the background and in the second 48 hours, the dashboard was visible to the care staff with the same patient. “The two-week study at TGHC proved a tremendous learning experience for everyone involved in behavioural science on how to operationalize a system in a health care setting during COVID,” commented co-founder Matthew Sefati. “It allowed us to witness how nurses responded to the dashboard and how it could impact interprofessional practice.”With the entire world looking forward to bidding farewell to 2020 and turning the page to a brighter year ahead, 2021 promises to be another brilliant year for Curiato. The team is looking forward to unveiling its product branding, signing up more customers, gaining more experience integrating its predictive analytics with real-world clinical practice, and generating more clinical evidence.
“We are pleased with our progress considering the difficult operating environment that characterized 2020. During the year, Curiato made significant scientific and clinical progress, completed its second clinical pilot, registered with Health Canada and FDA for sale, and achieved post-revenue status. These are major milestones for any health tech company. We were able to get these done because our team and partners stepped up and supported us in a big way,” commented Moazam Khan, co-founder and CEO of Curiato. “For this, we are extremely grateful. If we keep this up, we’re well on our way to realizing our vision of connecting data, patients, and caregivers to inform care decisions with every bed.”
Executive Director of Velocity, Adrien Côté, is among those impressed with how Curiato built their team as well too.
Both sets of research were enabled by funding from the Centre for Aging + Brain Health Innovation (CABHI). A manuscript is also in preparation for a leading peer-reviewed journal in the wound care field.
“It really speaks to the founding team of how they've really methodically and thoughtfully worked with the ecosystem to bring their solution to market. And that extends to well, to as well to Curiato building their team bringing in top talent and at rallying these people to their story and their vision and their passion. I think I'm really excited to see what Curiato is going to do in the next five years.”
The continuing growth trajectory has been possible through the support of CABHI, Velocity–University of Waterloo, Communitech, OBIO, OCE, Berkeley Skydeck, Biomedical Zone, Ryerson University, St. Michael’s Hospital, CELS, NRC-Canada, Next Founders, MaRS, Accelerator Centre, St. Paul’s Greenhouse, H2i, and the Government of Ontario.
Stay tuned for more news in 2021.